Neoadjuvant Chemotherapy vs. Neoadjuvant Chemoradiation in Patients With Surgically Resectable Esophageal Cancer: a Pilot Randomized Study
The best treatment for resectable esophageal cancer is unknown. Although an operation to
remove the esophagus is the most common treatment, previous studies have shown that patients
live longer when either chemotherapy or chemotherapy plus radiation (chemoradiation) is
given before surgery (preoperative), compared to surgery alone. However it is unknown which
of these treatments (preoperative chemotherapy or preoperative chemoradiation) is more
effective in improving survival. A study where patients with resectable esophageal cancer
are chosen at random to receive one of the two preoperative treatments would help determine
if one form of treatment improves survival compared to the other.
Patients with localized esophageal cancer will be randomized to receive either preoperative
chemotherapy or preoperative chemoradiation followed by surgery.
The main objective of this pilot trial is to determine the possibility of conducting a
larger study with many centres participating. If this study proves to be feasible with
enough patients enrolled and able to tolerate treatments without major side effects then we
can hopefully proceed to perform a larger multi-centre trial to look for survival outcome
differences between patients who receive preoperative chemotherapy and those who receive
preoperative chemoradiation. The results of this trial would ultimately help us choose the
most effective treatment of resectable esophageal cancer and hopefully improve survival.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society